Optimization of Tubulysin Antibody-Drug Conjugates: A Case Study in Addressing ADC Metabolism.

Autor:	Tumey LN; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States., Leverett CA; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States., Vetelino B; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States., Li F; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States., Rago B; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States., Han X; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States., Loganzo F; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States., Musto S; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States., Bai G; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States., Sukuru SC; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States., Graziani EI; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States., Puthenveetil S; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States., Casavant J; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States., Ratnayake A; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States., Marquette K; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States., Hudson S; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States., Doppalapudi VR; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States., Stock J; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States., Tchistiakova L; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States., Bessire AJ; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States., Clark T; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States., Lucas J; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States., Hosselet C; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States., O'Donnell CJ; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States., Subramanyam C; Pfizer, Inc. , 445 Eastern Point Road, Groton, Connecticut 06379, United States.
Jazyk:	angličtina
Zdroj:	ACS medicinal chemistry letters [ACS Med Chem Lett] 2016 Jun 22; Vol. 7 (11), pp. 977-982. Date of Electronic Publication: 2016 Jun 22 (Print Publication: 2016).
DOI:	10.1021/acsmedchemlett.6b00195
Abstrakt:	As part of our efforts to develop new classes of tubulin inhibitor payloads for antibody-drug conjugate (ADC) programs, we developed a tubulysin ADC that demonstrated excellent in vitro activity but suffered from rapid metabolism of a critical acetate ester. A two-pronged strategy was employed to address this metabolism. First, the hydrolytically labile ester was replaced by a carbamate functional group resulting in a more stable ADC that retained potency in cellular assays. Second, site-specific conjugation was employed in order to design ADCs with reduced metabolic liabilities. Using the later approach, we were able to identify a conjugate at the 334C position of the heavy chain that resulted in an ADC with considerably reduced metabolism and improved efficacy. The examples discussed herein provide one of the clearest demonstrations to-date that site of conjugation can play a critical role in addressing metabolic and PK liabilities of an ADC. Moreover, a clear correlation was identified between the hydrophobicity of an ADC and its susceptibility to metabolic enzymes. Importantly, this study demonstrates that traditional medicinal chemistry strategies can be effectively applied to ADC programs.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu